Browsing Tag
Q32 Bio
2 posts
Q32 Bio divests complement inhibitor ADX-097 as Akebia Therapeutics builds rare kidney disease pipeline
Discover how Q32 Bio’s ADX-097 sale to Akebia Therapeutics reshapes both companies’ pipelines, balance sheets, and investor outlook.
Q32 Bio’s bempikibart shows signs of a remittive effect in alopecia areata—Here’s what that means
Q32 Bio Inc. has released promising SIGNAL-AA trial results, shedding new light on the potential of bempikibart clinical…